Recent advancements in the treatment of rheumatoid arthritis (RA) have been revolutionized by the introduction of monoclonal antibodies (mAbs). These biologics target specific cytokines and cellular components in the RA synovium, offering a promising approach to achieving remission in clinical, functional, and radiographic aspects of the disease. Early studies focused on mAbs targeting CD4, CD7, […]